
Spectradyne LLC Profile last edited on: 12/29/17
CAGE: 70HY9
UEI: LDUHFUHN3EY7
Business Identifier: Measuring and analyzing nanoparticles Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 33
County: Los Angeles
Congr. District: 33
County: Los Angeles
Public Profile
Spectradyne LLC has developed proprietary technology for efficiently and accurately measuring and analyzing nanoparticles. The capabilities of their technology include: measurement of single particles, no averaging, 50 nm â 1,000 nm diameter, measurement/analysis of up to 10,000 particles/second, absolute concentration, and any level of polydispersity. The company's nCS1 technology is a bench top instrument with a 1â square footprint, operated by a computer through a standard USB interface. It is based on Resistive Pulse Sensing, and is implemented through a combination of semiconductor nano-fabrication techniques, low-cost plastic molding, low-noise electrical sensing, and innovative signal-extraction algorithms. The primary application of Spectradyne's technology is the measurement of protein aggregation in the drug development industry, but there are other applications in virology and in consumer product quality control. The company's Nanoparticale Analyzer (NA) technology was invented at the University of California, Santa Barba
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2021 | 2 | NIH | $1,905,454 | |
Project Title: Quantifying Specific Nanoparticle Phenotypes in Complex Biological Fluids by Fluorescence Microfluidic Resistive Pulse Sensing | ||||
2018 | 2 | NSF | $1,472,654 | |
Project Title: A low-cost instrument for rapid sub-micron particle size and concentration measurement | ||||
2016 | 2 | NIH | $1,725,683 | |
Project Title: Low Cost Electronic Detection of Molecular Aggregation for Rapid Drug Development |
Key People / Management
Franklin Monzon -- Co-Founder and CEO
Jean-Luc Fraikin -- Chief Scientist
Jean-Luc Fraikin -- Chief Scientist
Company News
There are no news available.